GEHCHealthcare · Medical DevicesThe 22 Wall Street analysts covering GE Healthcare Technologies, Inc. hold a median 12-month price target of $89 — +3.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores GE Healthcare Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GEHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.2% from it.
Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | UBS | Maintains | Neutral | $73 → $80 |
| 29 Oct 2026 | Barclays | Maintains | Overweight | $85 → $95 |
| 29 Oct 2026 | Citigroup | Maintains | Neutral | $71 → $79 |
| 29 Oct 2026 | JP Morgan | Maintains | Neutral | $70 → $80 |
| 29 Oct 2026 | RBC Capital | Maintains | Outperform | $80 → $90 |
| 28 Oct 2026 | BTIG | Maintains | Buy | $75 → $83 |
| 12 Oct 2026 | BTIG | Maintains | Buy | — |
| 12 Oct 2026 | BTIG | Maintains | Buy | $79 → $75 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $85 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | — |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $75 → $71 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | — |
| 5 Oct 2026 | Needham | Reiterates | Buy | $93 |
| 5 Oct 2026 | Needham | Reiterates | Buy | — |
| 22 Sept 2026 | Needham | Initiates | Buy | — |
| 22 Sept 2026 | Needham | Initiates | Buy | $93 |
| 17 Sept 2026 | BTIG | Reiterates | Buy | $79 |
| 17 Sept 2026 | BTIG | Reiterates | Buy | — |
| 19 Aug 2026 | BTIG | Reiterates | Buy | $79 |
| 19 Aug 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GEHC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, GE Healthcare Technologies, Inc. returned +15.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 42% of US stocks
Cheaper than 56% of US stocks
Cheaper than 29% of US stocks
Cheaper than 30% of US stocks
Higher than 46% of US stocks
Higher than 71% of US stocks
Higher than 51% of US stocks
Higher than 73% of US stocks
Higher than 69% of US stocks
Higher than 81% of US stocks
Higher than 76% of US stocks
Higher than 63% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GE Healthcare Technologies, Inc. has a market value of $36.5B and an enterprise value of $43.8B.
Revenue in the twelve months to 30 June 2026: $21.3B. The latest quarter grew 7.2% year on year.
Net income over the same four quarters: $2.0B, a 9.6% net margin.
Diluted earnings per share, trailing twelve months: $4.36.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
GE Healthcare Technologies, Inc. spent $400.0M on share buybacks and $64.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.1×; forward P/E: 14.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.20%, paying out 3% of earnings.
GE Healthcare Technologies, Inc. employs 54,000 people — $394K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GE Healthcare Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
GE HealthCare raised its 2026 earnings outlook following strong third-quarter results. The company also faces tariff risks, concerns about fourth-quarter growth and ongoing margin pressures.
Why it matters — The raised outlook is tempered by risks that could affect GEHC’s growth and margins.
GE HealthCare announced Lung Guidance and AutoAS, two AI-assisted capabilities for its Vscan Air handheld ultrasound system. They are designed to support consistent lung ultrasound image acquisition and provide additional insights when assessing moderate-to-severe aortic stenosis at the point of care.
Why it matters — The announcement highlights new AI-assisted functionality in GEHC’s point-of-care ultrasound offering for clinicians evaluating cardiac and respiratory symptoms.
GE HealthCare introduced Allia Celeo, a ceiling-mounted image-guiding system, at the TCT 2026 conference. The system combines an extra-wide-bore C-arm, an intuitive user interface, and an AI-powered image chain, and is designed for procedural flow and versatile use in interventional suites.
Why it matters — GEHC watchers may note the launch as a new interventional imaging system aimed at suites prioritizing patient throughput and versatility.
Zacks Investment Research compares GE HealthCare Technologies (GEHC) and Haemonetics (HAE) for investors interested in medical-products stocks, asking which may be more attractive to value investors.
Why it matters — The item frames GEHC in a value-investing comparison with HAE, which may be relevant to readers assessing GEHC against a peer.
GE HealthCare reported 3Q26 organic revenue growth of 6.2% and margin expansion, citing broad-based demand. It raised its 2026 outlook for organic revenue growth, adjusted EPS, and free cash flow.
Why it matters — The results, higher outlook, and anticipated contribution from Pharmaceutical Diagnostics, Flyrcado, and the SOFIE acquisition are relevant to GEHC’s growth and financial outlook.
The 22 Wall Street analysts covering GE Healthcare Technologies, Inc. have a median 12-month price target of $89, with estimates ranging from $75 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering GE Healthcare Technologies, Inc., 16 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GE Healthcare Technologies, Inc. 82 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, GE Healthcare Technologies, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +3.2% from the last close, and Ticker Nerd's factor model ranks GE Healthcare Technologies, Inc. 82 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GE Healthcare Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GEHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $100 over the next 12 months.
GE Healthcare Technologies, Inc. returned +15.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "GEHC Q3 Earnings Call Highlights Raised Outlook and Margin Risks". GE HealthCare raised its 2026 earnings outlook following strong third-quarter results. The company also faces tariff risks, concerns about fourth-quarter growth and ongoing margin pressures.
GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products. Its portfolio supports hospitals, health systems, and clinical providers with tools used in diagnosis, treatment, and patient care across routine and complex medical settings. GE HealthCare also offers software, digital workflows, and service capabilities that help healthcare organizations manage equipment, improve clinical efficiency, and integrate data across care environments. The company’s main business areas include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting its broad role in modern healthcare infrastructure. Headquartered in Chicago, Illinois, GE HealthCare focuses on technologies and services that are widely used in medical imaging, bedside monitoring, and diagnostic procedures worldwide.
CEO Mr. Peter J. Arduini · 54,000 employees · United States · https://www.gehealthcare.com
